Navigation Links
Exelixis Announces Third Quarter 2007 Financial Results and Business Update
Date:11/5/2007

e sale of assets recognized in conjunction with our transaction with Agrigenetics Inc., a wholly-owned subsidiary of The Dow Chemical Company, which was accounted for as a sale of our plant trait business.

Cash and cash equivalents, short-term and long-term marketable securities, investments held by Symphony Evolution, Inc. (a consolidated clinical development financing vehicle) and restricted cash and investments totaled $297.6 million at September 30, 2007, compared to $263.2 million at December 31, 2006.

Q3 2007 Business Highlights

* In mid-September, we submitted a data report for XL880 to our partner

GlaxoSmithKline (GSK), which had requested an accelerated review of

XL880. GSK has 90 days from the date of submission of the data report

for XL880 to determine whether it will select XL880 for further

clinical development and commercialization.

* We presented encouraging data from a phase 2 proof-of-concept trial of

XL647 as first-line therapy for non-small cell lung cancer (NSCLC) at

the IASLC World Conference on Lung Cancer in Seoul, South Korea. On

October 24, 2007, we presented updated data from this same trial at

the AACR-NCI-EORTC Conference, where investigators reported that over

68% of evaluable patients had a clinical benefit. Out of 34 evaluable

patients, there were 10 partial responses and 13 cases of stable

disease. Responses were observed in patients with and without

activating EGFR mutations, and the compound was generally well

tolerated.

* We retained the right to develop and commercialize XL647 after GSK

declined its option to further develop the compound. Having clarified

ownership of the compound, we have begun an aggressive development

program that calls for pivotal trials of XL647 to be initiated in the

first half of 2008.

* We ex
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), a ... develop, and commercialize novel flavor ingredients for the food, ... for the second quarter 2015. "Moving ... track to achieve our commercial and financial goals," stated ... Company. "Since our last quarterly earnings report, our two ...
(Date:7/30/2015)... July 30, 2015 HIGHLIGHTS:Q2 2015 ... 2014) , Reported sales were $697 million compared ... Sales grew organically by 8%, and changes in foreign ... increased sales by 1%. , By business unit, ... Applied and 11% in SAFC Commercial. , Reported ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... BANGALORE , July 30, 2015 ... Cell Market - Growth, Trends & Forecasts (2015-2020), , published ... worth US$ 30.25 billion by the end of 2020, with ... globally accounting for more than 40% of the global market ... grow at a CAGR of 13.7% during the period of ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... Varian,Medical Systems (NYSE: VAR ) and ... Europe,s first IGRT (image guided radiotherapy),training school, enabling ... the,latest and most precise radiotherapy technologies available to ... Liverpool is the venue for,the first event of ...
... evolution, many of a species properties are shaped ... mammalian teeth, whose many features closely reflect what ... scientists have suspected that genetic and developmental interactions ... the University of Helsinkis Institute of Biotechnology show ...
... the Wilson Centers Project on Emerging Nanotechnologies, in ... and Consumer Reports Online announces a major effort ... engage them in an important online conversation about ... consumer products. , This exciting online event, ...
Cached Biology Technology:First European IGRT School Takes Place for Radiotherapy Practitioners in UK 2First European IGRT School Takes Place for Radiotherapy Practitioners in UK 3Mice teeth explain the troubles with human wisdom teeth 2Project on Emerging Nanotechnologies and Consumers Union collaborate on 'ConsumersTalkNano' 2
(Date:7/20/2015)... , July 20, 2015  Acuity Market Intelligence,s ... The Convergence of Commerce and Privacy" forecasts that ... biometric apps will be downloaded to smart mobile ... mobile biometrics market is projected to generate more ... during the seven-year forecast period.    ...
(Date:7/13/2015)... Conn. , Jul. 13, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/188684 for ... achieves another new convenient and secure method to ... new, innovative payment methods, introduced with its groundbreaking ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... have manipulated cell activity that occurs during the interruption ... animal studies. The finding has the potential to become ... already existing drugs might be pressed into service to ... ischemia, is a major problem in many organs, where ...
... science may be a significant step closer to climbing into ... researchers at Washington University School of Medicine in St. Louis ... that a single protein, HS1, enables key functions of natural ... viral infections. The protein allows the NK cells to pursue ...
... fossil and the reinterpretation of previously known fossils, all from ... "missing link" in the evolution of flatfishes and explain one ... include halibut, flounder and sole, have a bizarre structural adaptation: ... is even more remarkable is that every flatfish is born ...
Cached Biology News:Novel approach may protect against heart attack injury 2Control switches found for immune cells that fight cancer, viral infection 2New fossil tells twisted tale of how flatfishes ended up with two eyes on one side of head 2New fossil tells twisted tale of how flatfishes ended up with two eyes on one side of head 3New fossil tells twisted tale of how flatfishes ended up with two eyes on one side of head 4
... The CpGenome Fast DNA Modification Kit contains ... on a DNA sample. In the bisulfite ... sulfonated, converting them to uracils, while 5-methylcytosines ... treated DNA will differ depending on whether ...
Poly A Polymerase catalyzes the addition of AMP to the 3' hydroxyl terminus of RNA. Poly A Polymerase can add poly(C) and poly(U) to RNA but does so with much-reduced efficiency....
... proteins (NMPs) make up the internal structural framework ... functions as DNA replication, RNA synthesis, and hormone ... shown to be highly insoluble in vitro ... releases soluble nuclear matrix proteins that can be ...
... in the forefront of chemical peptide synthesis ... synthesis in solution. , Our Functional Peptides ... HPLC at no extra cost, thus we ... quality standard. , Our team of expert ...
Biology Products: